|Videos|July 23, 2017

Importance of Surgical Teams Voicing Safety Concerns in Operating Rooms

Arjun Srinivasan, MD, stresses the importance of surgical teams speaking up if they have safety concerns regarding procedure in operating rooms.

Arjun Srinivasan, MD, Associate Director, Healthcare-Associated Infection Prevention Programs, Centers for Disease Control and Prevention, stresses the importance of surgical teams speaking up if they have safety concerns regarding procedure in operating rooms.

Interview Transcript (slightly modified for readability)

“For surgical teams, when they think that something is going wrong, the most important thing is to stop; if something is not going the way that you think it should be going, if there’s a concern about the safety of the procedure, you should pause. Obviously in the middle of a surgery, you can’t just call the thing off, but there is an opportunity to pause [and say,] ‘Just hang on a second. I’m not happy with the way that’s occurring, let’s take a quick second and make sure that we’re doing things exactly right.’

We may want to regroup very quickly and make sure that we’re following the procedures correctly. The good thing in most operating rooms is that there’s a lot of experience; surgery is very, very safe, so, we have very, very good systems in place. Surgical teams are some of the best at doing that, and they do the same thing; they do it the right way every single time. And there’s usually enough recognition, because people are so savvy because they do this all the time that when things are not quite right, usually somebody recognizes it.

The key is for every member of the team to feel empowered to speak up, to say, ‘Wait a minute, I don’t think that’s quite right. That doesn’t look like the way we normally do it. Can we stop for a second, and get back on the right track?’”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.